BioSpace News Archive

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the first quarter ended March 31, 2020 before the market open and host a conference call on Thursday, May 14, 2020. Conference Call Details Date: Thursday, May 14 Time: 8:30 am Eastern Time Domestic: 855-327-6837 International: 631-891-4304 Conference ID: 10009533 W

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Owen A. O’Connor, MD, PhD, has joined the Company as Chief Scientific Officer. Dr. O’Connor brings extensive scientific experience in developing drug candidates in oncology and hematology, and most recently served as a Professor of Medicine and Experimental Therapeutics, the Director of the Center for Lymphoid Malignancies, and Co-Program Director of the Lymphoid Development and Malignancy Pro

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, today reported financial results for the first quarter ended March 31, 2020. “Our team remains focused on progressing our programs as we navigate the evolving business and regulatory environment,” said George Lasezkay, Pharm.D., J.D., Presiden

Recro Pharma, Inc. a leading contract development and manufacturing organization, with integrated solutions for the development, formulation, regulatory support, manufacturing and packaging of oral solid dose drug products, announced that it will report first quarter 2020 financial results on Monday, May 11, 2020.

Clinical successes highlight Axsome’s accelerated evolution into a leading CNS company Positive pivotal Phase 2/3 results for AXS-05 in Alzheimer’s disease agitation further deepen innovative pipeline Positive efficacy results in 5 significant CNS indications with 4 candidates advance broad late-stage pipeline Two NDA submissions, for AXS-05 in MDD and AXS-07 in migraine, on track for 4Q 2020 Pre-commercialization activities underway for potentially first-in-class or best-in-class C

ANJESO™ Approved by FDA for the Management of Moderate to Severe Pain; Product Now Available for Ordering and Delivery for Customers Strengthened Balance Sheet Through Successful Completion of Underwritten Public Offering Resulting in Net Proceeds of $23.1 Million Company on Track to Commence Commercial ANJESO Launch by Early June 2020 MALVERN, Pa., May 08, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care setting

The randomized, double-blind, placebo-controlled study aims to enroll up to 40 patients with moderate-to-severe COVID-19 pneumonia in the U.S. -- All six analyzed moderate-to-severe COVID-19 patients treated with opaganib under compassionate use in Israel were weaned from oxygen and discharged from the hospital -- Opaganib’s unique mechanism of action has both anti-inflammatory and anti-viral activities, targeting a critical host factor, minimizing potential development of resistance du

1,000 COVID-19 test kits will be distributed each week to Federally Qualified Health Centers in Georgia

Luminex Corporation (NASDAQ: LMNX) (“Luminex”) announced today the pricing of its offering of $260,000,000 aggregate principal amount of 3.00% Convertible Senior Notes due 2025 (the “Convertible Notes”) in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The delivery of th

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the the voting results from its Annual General Meeting of Shareholders held on Thursday May 7, 2020.